Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO Hendrik Liebers has resigned.
Neurology and inflammation company Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) named Eric Carter interim CMO. He was SVP, CMO and global head of clinical & non-clinical development at Allergan plc (NYSE:AGN).
Cardiovascular and endocrine/metabolic company Amarin Corp. plc (NASDAQ:AMRN) promoted Aaron Berg to SVP and chief commercial officer from SVP of marketing and sales. He was CEO of Essentialis Inc., which merged with Capnia Inc. to form Soleno Therapeutics Inc. (NASDAQ:SLNO).
Pain, gout and inflammation company Grünenthal Group (Aachen, Germany) hired Philip Larsen as CSO, effective July 1. He is CSO and global head of diabetes research and translational medicine at the German Hub of Sanofi (Euronext:SAN; NYSE:SNY).
Gastrointestinal company OrphoMed Inc. (Mill Valley, Calif.) said President and CEO Nikhilesh Singh will transition to the role of CSO. He is succeeded by Gary Phillips, who was EVP and CSO of Mallinckrodt plc (NYSE:MNK).
Microbiome company Kaleido Biosciences Inc. (Bedford, Mass.) appointed Joshua Brumm as CFO. He was CFO and COO at Versartis Inc. (NASDAQ:VSAR).
Gene regulation company Exicure Inc. (Skokie, Ill.) hired Matthias Schroff as COO. He was CEO at Vaximm AG (Basel, Switzerland).
Novo Holdings A/S (Hellerup, Denmark) hired Craig Boyd as president of its anti-infectives subsidiary Xellia Pharmaceuticals. He was chief commercial officer at Envigo (East Millstone, N.J.).